Skip to main content

AI Can Help ID Patients With Diabetes at Highest Risk for Cardiomyopathy

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 30, 2024.

via HealthDay

WEDNESDAY, Oct. 30, 2024 -- Machine learning can help identify individuals with diabetes at high risk for diabetic cardiomyopathy (DbCM), according to a study published online Sept. 6 in the European Journal of Heart Failure.

Matthew W. Segar, M.D., from the Texas Heart Institute in Houston, and colleagues developed and validated a machine learning-based clustering approach to identify high-risk DbCM based on echocardiographic and cardiac biomarker parameters. The training model included 1,199 individuals with diabetes participating in the Atherosclerosis Risk in Communities cohort who were free of cardiovascular disease. The model was validated using data from 802 participants in the Cardiovascular Health Study and a separate cohort of 5,071 electronic medical records.

The researchers found that phenogroup-3, the high-risk DbCM phenotype (324 patients), had significantly higher five-year heart failure incidence than other phenogroups (12.1 versus 4.6 percent for phenogroup 2 and 3.1 percent for phenogroup 1). For the high-risk DbCM phenotype, key echocardiographic predictors included higher N-terminal pro-B-type natriuretic peptide levels, increased left ventricular mass and left atrial size, and worse diastolic function. In the validation cohorts, the deep neural network classifier identified 16 and 29 percent of participants with DbCM, respectively. Participants with the high-risk DbCM phenotype in the external validation cohorts had a significantly higher incidence of heart failure.

"A machine learning-based clustering approach to identify DbCM may promote a risk-based approach for the use of effective but potentially expensive heart failure preventive therapies among the highest-risk subgroup of individuals with diabetes who are more likely to benefit," the authors write.

Several authors disclosed ties to the pharmaceutical and biotechnology industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

American Diabetes Association, June 20-23

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians...

Muscle Ultrasound Can Detect Insulin Resistance

MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...

Disparities Seen in Continuous Glucose Monitor Rx by Language Preference

FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.